Acromegaly
Drug research and approvals for acromegaly: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 13 studies of acromegaly are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 5 approved and 4 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 13
- Trials authorized in Canada: 3
- FDA orphan approvals: 5
- EU medicines: 4
- A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy VolunteersNCT07909837 · Phase 1 · Nanjing Chia-tai Tianqing Pharmaceutical · starts Apr 23, 2026
- Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic DietNCT07866846 · Not applicable · Leiden University Medical Center · starts Jul 29, 2025
- A Study to Evaluate MAR002 for AcromegalyNCT07641179 · Phase 2 · Marea Therapeutics · starts Jul 23, 2026
- An Observational Study of Octreotide Subcutaneous Depot in Patients With AcromegalyNCT07583563 · Not reported · Camurus AB · starts Jun 5, 2026
- Study of MAR002 in Healthy MenNCT07195175 · Phase 1 · Marea Therapeutics · starts Aug 11, 2025
- Effects of Pasireotide Lar Therapy on Bone MetabolismNCT07179926 · Not reported · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · starts Sep 8, 2025
- KETOgenic Diet Therapy in Patients With ACROmegalyNCT06949891 · Not applicable · Erasmus Medical Center · starts Jun 1, 2023
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With…NCT06930625 · Phase 3 · Debiopharm International SA · starts Nov 26, 2025
- Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional StudyNCT05964712 · Not reported · Istituto Auxologico Italiano · starts Jun 18, 2019
Approved 5
- OctreotideSomatostatin receptor agonist
- LanreotideSomatostatin receptor 5 agonist
- PegvisomantGrowth hormone receptor antagonist
- PasireotideSomatostatin receptor 5 agonist
- BromocriptineD2-like dopamine receptor agonist
Phase 3 1
- PaltusotineSomatostatin receptor 2 agonist
Phase 2 3
- VeldoreotideSomatostatin receptor 2 agonist
- Cimderlirsen sodium
- ClomipheneEstrogen receptor alpha modulator
Phase 1 or earlier 1
How its trials ended
189 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 47 whose ending is known, 62% met their primary endpoint, 0% missed it and 38% stopped early.
- Completed, result not reported9148%
- Met its primary endpoint2915%
- Status unknown2915%
- Ongoing2212%
- Stopped: other or unclear116%
- Stopped: enrollment or feasibility42%
- Stopped: sponsor or business decision21%
- Stopped: lack of efficacy11%
| Aug 8, 2017 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously…Mycapssa (octreotide) | Chiasma | Closed |
| May 25, 2016 | Strict IGF-1 control in acromegalySomavert | St Michaels Hospital | Closed |
| Apr 10, 2013 | An open label, multi-center pasireotide roll-over protocol for patients who have completed a previous novartis-sponsored pasireotide study and are judged by…Pasireotide (SOM230) | Recordati Rare Diseases | Closed |
| Sep 25, 2025 | PalsonifyTreatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option | Crinetics Pharmaceuticals, Inc. | Approved |
| Jun 26, 2020 | MYCAPSSA (formerly Octreolin)Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated… | Chiesi USA, Inc. | Approved |
| Dec 15, 2014 | PasireotideTreatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option | Novartis Pharmaceuticals Corporation | Approved |
| Mar 25, 2003 | SomavertTreatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies,… | Sensus Corporation | Approved |
| Nov 25, 1998 | Sandostatin LARReduction of growth hormone and IGF-1 (somatomedin C) in acromegaly. | Novartis Pharmaceuticals Corporation | Approved |
| Nov 3, 2016 | H-(4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cy…Treatment of acromegaly | Amryt Research Ltd. | Designated |
| Jun 24, 2013 | VeldoreotideTreatment of acromegaly | Xeris Pharmaceuticals, lnc. | Designated |
| Dec 7, 2009 | Octreotide acetate subcutaneous implantTreatment of acromegaly | Endo Pharmaceuticals Solutions, Inc. | Designated |
| Nov 4, 2003 | VapreotideTreatment of acromegaly | H3 Pharma, Inc. | Designated |
| Apr 23, 2026 | PalsonifyPaltusotine · orphan | Crinetics Pharmaceuticals Europe GmbH | EMA ↗ |
| Jun 30, 2025 | OczyesaOctreotide | Camurus AB | EMA ↗ |
| Apr 24, 2012 | SigniforPasireotide | Recordati Rare Diseases | EMA ↗ |
| Nov 12, 2002 | SomavertPegvisomant | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA